Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.
When compared against market expectations, Merck’s fourth-quarter results were a mixed bag. The company reported non-GAAP EPS ...
Below are the earnings highlights for Merck & Co Inc. (MRK): Earnings: $3.743 billion in Q4 vs. -$1.226 billion in the same period ...
Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite ...
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...
Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...
Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...
MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback